Top Bucket AI

About

Eric Crombez, M.D., became an Abeona director on August 8, 2024. He serves as Chief Medical Officer and Executive Vice President of Ultragenyx Pharmaceutical Inc. (Nasdaq: RARE), responsible for strategic leadership of clinical development and translational research and overseeing global development functions. He previously served as Chief Medical Officer of Dimension Therapeutics, leading clinical development of gene therapy programs in hemophilia B, hemophilia A, OTC deficiency and GSDIa, and earlier worked in Shire's Human Genetics Therapy business unit and as an assistant professor of pediatrics at the David Geffen School of Medicine at UCLA. A board-certified clinical geneticist, he earned a B.S. in biology from the University of Michigan and an M.D. from Wayne State University School of Medicine.

Roles

Abeona Therapeutics Inc.

Director · Current role

August 2024–present

Ultragenyx Pharmaceutical Inc. (Nasdaq: RARE)

Chief Medical Officer and Executive Vice President

present

Dimension Therapeutics

Chief Medical Officer

—

Shire

Human Genetics Therapy business unit

—

David Geffen School of Medicine at UCLA

Assistant Professor, Department of Pediatrics, Division of Medical Genetics

—

External Roles

Epicrispr Biotechnologies

Independent Director

present

Director Compensation

FY 2025

Fees earned or paid in cash

$57,500

ComponentAnnual board fee plus committee and committee-chair fees earned in 2025, paid quarterly

Stock awards

$200,000

ComponentRestricted stock award for 2025 Board service (36,101 shares granted January 31, 2025 at $5.54, ASC 718 grant-date fair value); vests one year after grant

Total

$257,500